A Germany-based KOL provides insights into epidemiology, prescribing habits, key marketed brands and late-phase pipeline therapies for HCC. Treatment strategies split by various disease stages as well as unmet needs are also discussed. Key pipeline assets highlighted include tislelizumab, Opdivo + Yervoy, camrelizumab + rivoceranib and tiragolumab. 

This interview was conducted on Oct. 16, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.